Multiple mechanisms including loss-of-function mutations in the genes encoding NRF2 or small Mafs, oxidation or epigenetic modification of the NRF2 promoter, or changes in the other factors that modulate NRF2 (such as kinases, phosphatases, or DNA binding proteins) have been suggested to contribute to the suppression of NRF2 activity during ageing
251 The results of immunoblotting and immunocytochemistry of central nervous system tissues suggested elevated p53 protein levels and the abnormal localization of p53 in ALS patients
MagnsdttirSRavcheevDde Crcy-LagardVThieleI
Proshkina E, Plyusnin S, Babak T, Lashmanova E, Maganova F, Koval L, et al
doi:10.7326/0003-4819-158-9-201305070-00003
Elevated oxidative stress markers This one is more clinical